Table 1.

CD8-validated TCR-recognizing RAS hotspot mutation, available for allogeneic treatment.

RAS mutation	# TCRs discovered	HLA-I restriction	% of individuals that have the allele (Allele Frequency). *Asian population	% Patients eligible for treatment. *Asian population	Minimal epitopes	Patient number	Method	Cancer diagnosis	References
KRAS p.G12D (35%)	1	C*08:02	8% (4.2%)	2.8	GADGVGKSA	3995	TIL screening	Colon	17
	4	C*08:02	8% (4.2%)	2.8	GADGVGKSA (3 TCRs)\GADGVGKSAL (1 TCR)	4095	TIL screening	Colon	17
	1	A*11:01	14% (7%), *>30%	4.9 *>10.5	VVVGAGGDGK	4373	TIL screening	Colon
KRAS p.G12V (24%)	1	A*11:01	14% (7%), *>30%	3.36 *>7.2	VVGAVGVGK	4148	PBL IVS	Endometrial	41
	1	C*01:02	5.3% (2.6%), *>30%	1.27 *>7.2	AVGVGKSAL	4391	TIL screening	Colon
	1	C*01:02	5.3% (2.6%), *>30%	1.27 *>7.2	AVGVGKSAL	4394	TIL screening	Colon
	1	C*01:02	5.3% (2.6%), *>30%	1.27 *>7.2	AVGVGKSAL	4385	TIL screening	Colon
				12.4*>27.5

Note: CD8 TCR Supplementary table showing columns (from left to right): the hotspot mutation recognized by the TCR and the percentage of this mutation among RAS-mutated cancer patients; number of TCRs discovered from the same patient recognizing the same target; the HLA-I restriction each TCR recognizes; percentage of the allele frequency (taken from allelefrequencies.net) and calculation of the percentage of the individuals in the Caucasian or Asian populations (*); percentage of patients eligible for treatment, calculated by multiplying the frequency of individuals that have the allele with the frequency of this RAS mutation (as in the first column) with the sum of percentages from all TCRs (the bottom of this column); ME sequence recognized by the TCR; patient number; the method used to find the TCR (TIL screen/PBL IVS); patient cancer diagnosis in which TCR was found; reference if the TCR has been published before and, if so, where.